HANGZHOU TIGERMED CONSULTING (300347) H2 2024 earnings summary

Executive summary

• Revenue declined 10.58% year-over-year to ¥6.60 billion, with net profit attributable to shareholders down 79.99% to ¥405 million, mainly due to significant non-recurring losses and a challenging domestic market environment.

• Clinical trial technical services revenue fell 23.75% year-over-year, while related and laboratory services grew 5.61%.

• Gross margin dropped from 38.18% to 33.27%, reflecting pricing pressure and order cancellations in the domestic market.

• Overseas business showed resilience, with North America clinical operations and new orders growing rapidly, partially offsetting domestic weakness.

• The company maintained its leading market share in China’s clinical research outsourcing sector and expanded its global footprint, especially in North America and Europe.

Financial highlights

• Operating cash flow was ¥1.10 billion, down 4.64% year-over-year.

• Net profit excluding non-recurring items was ¥854.9 million, down 42.13% year-over-year.

• Non-recurring losses included a ¥476.9 million loss from fair value changes in non-current financial assets.

• R&D investment was ¥238 million, accounting for 3.61% of revenue.

• Total assets at year-end were ¥28.67 billion, with net assets attributable to shareholders at ¥20.67 billion.

• Basic and diluted EPS were both ¥0.47, down from ¥2.34 last year.

Outlook and guidance

• The company expects the domestic clinical research outsourcing industry to recover, with market growth projected at 12.6% CAGR through 2028.

• Focus remains on global expansion, digital transformation, and AI-driven efficiency improvements.

• Management is committed to stable dividends and continued share repurchases to enhance shareholder value.